What does AEON Biopharma, Inc. do?
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of…
What is AEON Biopharma, Inc.'s P/E and P/B ratio?
AEON Biopharma, Inc. has a P/E ratio of -0.1 and a P/B ratio of -0.76.
What is AEON Biopharma, Inc.'s debt-to-equity ratio?
AEON Biopharma, Inc. has a debt-to-equity ratio of -0.65.
How much does AEON Biopharma, Inc. owe compared with what it owns?
AEON Biopharma, Inc. owes $3.60 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is AEON Biopharma, Inc.'s Positivity rank?
AEON Biopharma, Inc. is ranked #6,359 of 6,774 companies globally and #3,634 of 4,000 in United States on PositoAI, with a Positivity Score of -17,436.
Does AEON Biopharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Yes. AEON Biopharma, Inc. has 1 active red flag (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 03 Apr 2026). It has no yellow flags.
Where can I read the latest news about AEON Biopharma, Inc.?
Recent headlines about AEON Biopharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does AEON Biopharma, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of AEON Biopharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.